AVI-7100 for Influenza

AVI-7100 FOR INFLUENZA

We are developing AVI-7100 for the treatment of influenza under a Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases (NIAID).

 
 
 
 
  • PROGRAM
  • DISCOVERY
  • preclinical
  • PHASE 1
  • PHASE 2
  • PHASE 3
 

INFECTIOUS DISEASES

  • AVI-7288
    MARBURG VIRUS
  • AVI-7537
    EBOLA VIRUS
  • AVI-7100
    INFLUENZA
  • VIRAL PMO-X
    DENGUE
  • BACTERIAL PPMO
    TB
  • UNDISCLOSED TARGETS
     
 
 
 

RECENT PRESS RELEASES

 
 
 

Influenza, also called the flu, is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and lungs. It can cause mild to severe illness, and at times can lead to death. Influenza viruses are known to frequently mutate and, when a new strain emerges, a flu pandemic can rapidly occur if the human population has little to no immunity against it. Given limitations associated with currently available influenza antivirals, an urgent need exists for new flu treatments.

AVI-7100 is designed to bind to viral RNA and inhibit the synthesis of the M1 and M2 matrix proteins. These proteins are involved in the complex viral replication, assembly and budding processes, which enable the virus to reproduce in a host cell and infect other cells in the body. Inhibition of the M1 and M2 matrix proteins is intended to disrupt the viral lifecycle and stop or slow the spread of the disease to other cells in the body. Preclinical data suggest this mechanism may enable broad-spectrum activity against multiple influenza viruses.

AVI-7100 is based on our proprietary next-generation PMOplus™ chemistry, which is also used across our infectious disease pipeline, including our lead investigational candidate for the Marburg virus. Early development of AVI-7100 was supported by the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) Transformational Medical Technologies.